DelveInsight's Biologics Drug Substance Manufacturing Market Insights report provides the current and forecast market ...

The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...

With 17 years' experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process ...

They will also apprehend the manufacturing and scale up challenges, looking at compatibility problems, lyophilisation issues, and consider the different possibilities offered for drug delivery ...

DUBLIN--(BUSINESS WIRE)--The "Biological Drugs - Global Strategic Business ... are allowing for the development of personalized biologics that can modify disease pathways or even repair defective ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

The entire development process, from generating a hybridoma ... The current clinical pipeline of biologic drugs includes 240 mAbs and 120 proteins in various other categories, including ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide ... in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide ...

WuXi Biologics differentiates itself from ... Pre-IND includes drug discovery and preclinical development. At that time we did not believe its pre-IND business had a moat. Now late-phase services ...